We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Michael
Crossland
m.crossland@ucl.ac.uk
Michael
Crossland
m.crossland@ucl.ac.uk
Disorders of choroid and retinaMood [affective] disordersNeurotic, stress-related and somatoform disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Inherited macular disease (IMD) affects about 6,000 young people in the UK. The impact of vision impairment on wellbeing is enormous: recent studies show more than 40% of adults with low vision have signs of depression. Less is known about wellbeing and mental health in young adults with visual impairment, although research has identified anxiety, frustration, anger and reduced quality of life in children with low vision. Isolation, educational challenges and mental health difficulties are likely to have increased further during the COVID-19 pandemic.
In this study we will use qualitative research techniques to explore the impact of vision impairment on wellbeing and mental health for young people with inherited macular disease. We will explore the relationships between participation, social connectedness, level of functioning and vision-related quality of life, wellbeing, depression and anxiety.
Aims of the study
1. To quantify the impact of IMD on vision-related quality of life, wellbeing and mental health.
2. To collect the views of young people with established IMD, their carers, and experts in vision rehabilitation, on the optimal design of support services for people with new IMD.
3. To pilot an integrated support package for people developing IMD and evaluate its impact on vision-related quality of life, wellbeing and mental health.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
(All stages): • Not having English language skills sufficient to complete the telephone or online assessments (assessed by study team at the stage of giving study information) • Hearing loss which will affect the ability to complete telephone assessments (assessed by study team at the stage of giving study information)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University College London and funded by THE MACULAR DISEASE SOCIETY .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 57394
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
